Personalized or precision medicine is a novel clinical approach targeted to the individual patient and based on integration of clinical, genetic and environmental factors that define a patient uniquely from other individuals featuring similar clinical symptoms. Such personalized medicine approach is increasingly applied for diagnosis, clinical stratification and treatment of the metabolic syndrome (MetS) associated risks and diseases, including obesity, type II diabetes, non-alcoholic fatty liver disease and their complications. One emerging factor that governs MetS manifestations is the microbiome, whose composition, function, growth dynamics, associated metabolite profile and diverse effects on the host immune and metabolic systems can all This article is protected by copyright. All rights reserved.
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Introduction: The metabolic syndrome and personalized medicine
In recent years modern medicine is rapidly shifting from classical approaches focusing on disease-centered diagnosis and treatment paradigms, to a more individually tailored approach termed personalized medicine. Personalized or precision medicine is defined as treatment targeted to the individual patient on the basis of genetic, phenotypic, biomarker-based and possibly environmental and psychological factors that distinguish one patient from others with similar clinical characteristics 1 . One example for conditions in which precision medicine has been proposed as a therapeutic approach is the metabolic syndrome. The metabolic syndrome (MetS) is a group of co-associated diseases including obesity, insulin resistance, type 2 diabetes, cardiovascular disease and non-alcoholic fatty liver disease (NAFLD) 2 . Common risk factors predispose to these diseases, and in fact each of these metabolic syndrome diseases is considered a risk factor for the others.
Common risk factors for features of the metabolic syndrome include abdominal obesity, hyperglycemia, hypertension, elevated triglyceride levels and low HDL levels 2 . The prevalence of the MetS is globally increasing and estimated to encompass around 25-35% of the adult population worldwide 2 , highlighting the need for controlling the risk factors, development and progression of MetS-linked diseases.
Limited efficacy of global dietary recommendations in the metabolic syndrome
In obese individuals, weight loss can improve glycemic control, lower blood pressure and normalize cholesterol levels 3 . Consequently, a change of dietary habits (mostly reduction in caloric intake) is probably the most commonly prescribed strategy for prevention and treatment of the MetS. Nevertheless, obese individuals who successfully complete weight-loss diets often regain weight [4] [5] [6] , rendering the
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long-term efficacy of current recommended diet regimes questionable and disappointing.
In addition to facilitating weight loss, diet plays an important role in maintaining healthy glucose homeostasis 7, 8 . Diets aimed at prevention and treatment of hyperglycemia often take into account the meal carbohydrates content 9 and the glycemic index (GI) 10 , which estimates the post-prandial glycemic response (PPGR) to specific food items. Nevertheless, the ability of such diets to aid in controlling glucose levels showed mixed results in several randomized trials 11 . Several caveats of the glycemic index may contribute to this inconsistency, including the difficulty to determine the glycemic index of real-life meals containing multiple food items with different GIs, and poor predictive accuracy of GI in diabetic individuals. 
The microbiome in MetS
Inter-individual differences in the risk for developing MetS, disease manifestations and the response to diet and medical treatment, are often ascribed to the human genetics and lifestyle. In addition to these factors, the microbiome composition also displays considerable variability in the human population 15 , stemming from several determinants including diet [16] [17] [18] , age 19 , and host genetics 20 .
The composition of the microbiome and its association with the host can influence various physiological functions and play a pivotal role in numerous diseases including metabolic diseases 21, 22 (figure 1). A seminal study by the group of Jeffrey Gordon showed that the gut microbiome is different in obese compared to lean persons and rodents 23, 24 and its interaction with the host can significantly affect the development of obesity 24, 25 31 .
Metabolic consequences of inter-individual variations in the microbiome
The gut microbiome features a high inter-individual variability in community to the study participants. The diets designed by the algorithm were successfully validated in a cohort of 26 participants, mostly pre-diabetic individuals. Importantly, the 'good' diets of some participants were 'bad' for others 14 .
Additional support to the importance of the microbiome when considering diets beneficial for glucose homeostasis can be found in the study of Kovatcheva-Datchary et al 32 . In addition to mediating the beneficial impacts of food choices on human health, certain microbial compositions may exert individualized negative effects on their host in response to dietary stimuli. One such example is consumption of noncaloric artificial sweeteners (NAS), leading to perturbed microbiome composition, thereby promoting MetS in several studies in rodents [33] [34] [35] . Some of these perturbations in microbiome composition and function had a causative role in promoting metabolic derangements 34 , and in humans the ability of NAS to promote glucose intolerance was influenced by the host microbiome. Validation of these findings in larger human cohorts may enable to determine which individual might benefit from NAS, in contrast to those who should avoid them.
Personalized aspects of the microbiome in MetS expand beyond the scope of glucose homeostasis. In obese and overweight subjects, dietary intervention in obesity was reported to be more beneficial in subjects who had high microbial gene richness 36 .
Adding to the complexity is the finding that not only the composition, function and richness of the microbiome play a role in disease, but also the growth dynamics of the bacteria in the gut associate with the MetS, and dietary changes may exert differential effects on these human dynamics 37 .
Another diet-mediated condition, atherosclerosis, is closely associated with multiple risk factors and conditions comprising the metabolic syndrome, and may lead to devastating complications including ischemic heart disease, heart failure, and cerebrovascular disease. Like other manifestations of the metabolic syndrome, atherosclerosis was suggested to be influenced by inter-individual microbiome differences. Microbial metabolism of L-carnitine 29, 38 and phosphatidylcholine 39 , nutrients abundant in animal products and specifically red meat produces trimethylamine-N-oxide (TMAO), a pro-atherogenic species. The production of TMAO by the microbiome was dependent on the diet (omnivorous vs.
vegan/vegetarian) and its associated microbiome configuration. This suggests that recommendations for dietary modification in individuals suffering of atherosclerosis would potentially modulate the microbiome composition, thereby affecting disease pathogenesis.
Mechanisms implicated in gut microbiome influences on the MetS
Despite many association implicating gut microbes as involved in whole body metabolic responses and MetS-related morbidities, the underlying mechanisms are exceptionally complex and currently elusive. Emerging data suggests that inflammation and microbial-derived metabolites, such as short-chain fatty acids and bile acids, may significantly influence MetS-related disorders and disease progression.
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Microbial-derived metabolites
Metabolites produced, degraded or modulated by the microbiota serve as 'communication channels' by which the host and its microbiome signal to each other 40, 41 . Alterations in bacterial metabolites contribute to several MetS related risks and pathologies 30, 42 . While the best-studied metabolites include short chain fatty acids, bile acids and trimethylamines, many other metabolites may come into play and significantly affect host metabolism. Although the existence of inter-individual differences in the microbiome composition is well established, much less is known about person-to-person metabolomics variability, stemming from individual differences in diet, host genetics, and the microbiome 43 .
Short chain fatty acids
Short chain fatty acids (SCFA), including acetate, propionate, and butyrate are produced by bacterial fermentation of polysaccharides in the gastrointestinal tract 44 .
SCFA may play a role in the maintenance of body weight, intestinal homeostasis and improved lipids and glucose metabolism 42, [45] [46] [47] . Most of the studies in obese humans and rodents suggest that elevated SCFA levels combined with-enriched pathways for generating SCFA correlate with an increased capacity to harvest energy 25, 48, 49 58 . Antibiotics or GF conditions abrogated the metabolic phenotypes of GPR41 and GPR43 null mice, suggesting that bacterial SCFA induce GPR43 and GPR41 activation controlling whole body energy and glucose homeostasis 58 .
The response of the host to SCFA can also be mediated via glucose sensing by the gut-brain axis. De Vadder et al. 45 showed that propionate sensing in the colon induced intestinal gluconeogenesis, which was sensed by the gut-brain neural circuit and led to improved glucose and weight control 45 . Perry et al. 51 recently found that HFD rats displayed increased incorporation of acetate in the colon, and chronic administration of acetate caused obesity-associated MetS complications. In this study, acetate infusion led to a parasympathetic excitation stimulating β-cells insulin secretion 51 . While most of the above studies indicate a beneficial role for SCFA in energy and glucose homeostasis, larger human studies are necessary to elucidate possible personalization in the SCFA response. Understanding of the personalized responses to SCFA may enable to develop SCFA supplementation as a novel individualized or generalized treatment modality for MetS manifestations.
Bile acids
Bile acids are mainly produced by hepatic cholesterol catabolism, transported
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into the gallbladder and into the intestinal lumen by postprandial peristalsis [59] [60] [61] .
Microbiome-associated at the distal small intestine and colon can transform primary bile acids into secondary bile acids [59] [60] [61] . Mice treated with antibiotics or GF mice feature low concentrations of secondary bile acids, with altered expression profile of genes involved in bile acids conjugation and reabsorption indicating that the gut microbiota is responsible for bile acid synthesis, diversity and possibly host epithelial uptake [62] [63] [64] . In addition to the role of bile acids in facilitating dietary fat digestion, they are now recognized to participate in regulation of metabolic homeostasis 65, 66 . As such, some bile acids show promising initial results in treatment of MetS disorders such as insulin resistance, hypercholesterolemia and NAFLD 66, 67 .
Most of the physiological effects of bile acids are mediated by the G-protein coupled receptor TGR5 and the nuclear receptor farnesoid X receptor (FXR). FXR is a transcription factor that controls endogenous synthesis and release of bile acids and
FXR activation results in inhibition of hepatic bile acids biosynthesis 63, 68 . Obese and insulin resistant mice displayed decreased gut microbiota diversity, accompanied by a reduction in secondary bile acids and hepatic enzymes involved in bile acids biosynthesis, with increased FXR and decreased TGR5 expression 69 . Activation of TGR5 by bile acids led to improved insulin sensitivity, while binding of bile acids to FXR resulted in lowered cholesterol, and reduced liver and serum triglycerides 66 .
Experiments in GF and antibiotics-treated mice suggest that the microbiome may modulate FXR and FXR-related genes that control bile acid synthesis 62, 63, 70 .
Intestinal FXR deficient mice fed with HFD displayed decreased weight gain, glucose intolerance and insulin resistance and were protected from development of fatty liver 71, 72 .
Blocking intestinal FXR by administration of FXR antagonist modified bile acids composition and promoted adipose browning, decreased obesity and insulin
This article is protected by copyright. All rights reserved.
Accepted Article resistance 73 . Ryan et al. 74 found that the beneficial effects of bariatric surgery on metabolism including improvement in glucose tolerance were associated with changes in gut microbiota and were diminished in FXR null mice 74 . Together, all these animal studies pointed towards a dominant role for the gut microbiota in regulating bile acids diversity and FXR signaling, which in turn regulates MetS complications.
Obese humans followed after bariatric surgery featured long-term changes in their gut microbiome independently of BMI. Yet, the causal connection between gut microbiota, bile acid production and signaling, the pathogenesis of MetS-related disorders, and potential perturbation of these pathways as modes of MetS treatment merit further investigation in prospective human trials. 
Microbiota modulation of inflammation
Obesity, insulin resistance, atherosclerosis, steatohepatitis are all MetS disorders associated with inflammation. Adipose tissue inflammation is mostly studied in the contexts of obesity and type II diabetes where it contributes to disease pathogenesis and involves both the innate and adaptive immune responses 75 . While microbial derived endotoxins (such as lipopolysaccharide, LPS) were detected in type 2 diabetes patients and in obese and insulin resistant mice leading to augmented adipose and systemic inflammation 76, 77 , the role of microbiota-driven adipose tissue inflammation in MetS complications remained conflicting 78, 79 . Diet may play a major role in determination of the microbiome effects on MetS-associated inflammation.
Mice fed with lard diet showed induction of adipose toll-like receptor (TLR) immune signaling and inflammation with increased serum LPS and adiposity. The metabolic effect was transferrable to GF mice, whereas gut microbiota from fish-oil diet given to lard-fed mice counteract the metabolic phenotype, suggesting that diet has a major implication on microbial composition, which in turn modulates adipose tissue inflammation and adiposity 80 .
Similarly, a key link was also suggested between intestinal inflammation, gut microbial alterations and NAFLD 81 . In one study, mice deficient in inflammasome signaling displayed changes in their gut microbiota composition which aggravated hepatic steatosis, driven by massive influx into the portal circulation of TLR4 and TLR9 agonists, ultimately leading to increased hepatic TNFα secretion and resultant hepatic damage and inflammation. The metabolic effects were transferable by coThis article is protected by copyright. All rights reserved.
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housing, suggesting an important crosstalk between gut microbes and host in NAFLD progression. Another study 82 shows that the bile acid taurine controls microbiome composition leading to activation of NLRP6 inflammasome. Mice treated with taurine showed amelioration of colitis and the effect depended on the microbiome and inflammasome activation 82 . The effect of taurine on metabolic complications remains to be determined. First, the microbiome is highly variable between individuals. As such, accurate characterization of the microbiome in an individual is often confounded by compositional changes induced by medications 84 , age 85 , and even the time of the day in which a sample is collected 86 . Specifically, the importance of considering medication use as a potential confounder in microbiome analysis of MetS patients was recently demonstrated by Forslund et al. 87 , reporting a confounding effect of metformin (an anti-diabetic drug) in two reports characterizing the 'diabetic microbiome' in human patients 26, 88 . In addition, diet itself is a potent driver of alterations to the microbiome 89, 90 , a feature that is also observed in personalized nutritional interventions 14, 32 . This may compromise long-term microbiome-based nutritional recommendations, and necessitate repeated periodic sampling and adjustment of dietary recommendations based on a patient's updated dietary routine and associated microbiome configuration. Finally, the microbiome is only one factor impacting personalized response to diet, thus requiring its integration into multivariable prediction algorithms that include multiple host and environmental variables, and only a combination of these person-specific measurements may enable to devise adequate personalized dietary recommendations. This article is protected by copyright. All rights reserved.
Nutritional interventions
Dietary modifications are considered key to prevention and treatment of features of the MetS. Recent studies 14, 32 is still at its infancy 83 . Questions remain as to long-term efficacy of this approach, which merit prospective human-based studies.
Fecal microbiome transplantation (FMT)
FMT is based on transferring microbiome purified from the feces of a healthy 
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Probiotics and prebiotics
Rather than transplanting an entire microbial community, a more specific microbial-based approach involves supplementation of diet with a limited number of viable bacterial strains (probiotics), or using nutrients such as non-digestible carbohydrates that promote the growth of so-called 'beneficial' endogenous bacteria (prebiotics). Despite great public interest and extensive research, the efficacy of preand probiotics in promoting health benefits remains questionable, and there is currently no clinical indication for their consumption. In mice, supplementation with probiotic strains of Lactobacillus and/or Bifidobacteria was suggested to have a beneficial effect on the onset and progression of both T1DM and T2DM 94, 95 . In humans, some studies demonstrated beneficial effect of probiotics on MetS, however this effect was not uniformly reproducible 96 , and in some studies a controversial link was even suggested to exist between probiotics consumption and weight gain 97 .
Considering 
Microbiome-associated metabolites
Analysis of microbial metabolites in combination with metagenomic analysis of the pathways and genes involved in the metabolism to these metabolites will possibly enable designing personal approaches to treat patients with MetS complications This article is protected by copyright. All rights reserved.
Accepted Article through targeting of their metabolites and their signaling pathways. We have recently demonstrated that certain pathological microbial communities in mice produce metabolites that modify the host immune system to resist colonization by an exogenous microbiome 82 . Given the potential adverse effects of FMT and the substantial inter-individual variability in microbiome composition precluding probiotic and prebiotic approaches, an approach based on administration of a microbial metabolite cocktail may circumvent the inter-individual microbial differences and thus constitute a safer and more efficient mode of therapeutics for the MetS. One such example is supplementation of the diet with SCFA that protected mice from HFD-induced insulin resistance 45, 50, 52 . It remains to be determined whether SCFA supplementation has a therapeutic potential in humans. Another microbial derived metabolites currently tested in humans are bile acids. In preliminary studies, the microbial derived bile acid obeticholic acid, which is a potent FXR activator that decreases liver fat and fibrosis in mice, improved the histological features of the liver in non-alcoholic steatohepatitis patients 67 .
Likewise, microbiome-modulated metabolites may affect plasma lipid levels and atherosclerosis. As described above, microbial production of trimethylamines such as TMAO derived from red meat 29 is directly linked to development of atherosclerosis 29 . 
